Effect of acylethanolamides on lipid peroxidation and paraoxonase activity

BioFactors

Volumn 33, Issue 3, 2008, Pages 201-209

  Zolese, Giovanna ^a   Bacchetti, Tiziana ^a   Masciangelo, Simona ^a   Ragni, Letizia ^a,b   Ambrosi, Simona ^a   Ambrosini, Annarina ^a   Marini, Milvia ^a   Ferretti, Gianna ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Lipid peroxidation; N acylethanolamides; Oxidative stress; Paraoxonase activity; Plasma

Indexed keywords

2,2' AZOBIS(2 AMIDINOPROPANE); ACYLETHANOLAMIDE; AMIDE; ANANDAMIDE; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; COPPER; HIGH DENSITY LIPOPROTEIN; N OLEOYLETHANOLAMINE; PALMIDROL; UNCLASSIFIED DRUG; 2,2'-AZOBIS(2-AMIDINOPROPANE); AMIDINE; ARACHIDONIC ACID DERIVATIVE; OLEIC ACID; PALMITIC ACID DERIVATIVE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; INCUBATION TIME; LIPID BLOOD LEVEL; LIPID PEROXIDATION; NORMAL HUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; BLOOD; DRUG EFFECT; MIDDLE AGED;

ADULT; AMIDINES; ARACHIDONIC ACIDS; ARYLDIALKYLPHOSPHATASE; HUMANS; LIPID PEROXIDATION; MIDDLE AGED; OLEIC ACIDS; PALMITIC ACIDS; POLYUNSATURATED ALKAMIDES;

EID: 67650666472     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520330306     Document Type: Article

References (40)

1. P.M. Abuja, K. Lohner abd R. Prassl, Modification of the lipid-protein interaction in human low-density lipoprotein destabilizes ApoB-100 and decreases oxidizability, Biochemistry 38 (1999), 3401-3408. (Pubitemid 129501402)
2. A. Ambrosini, E. Bertoli, P. Mariani, F. Tanfani, M. Wozniak and G. Zolese, N-acylethanolamines as membrane topological stress compromising agents, Biochim Biophys Acta 148 (1993), 351-355.
3. G. Astarita, B. Di Giacomo, S. Gaetani, F. Oveisi, T.R. Compton, S. Rivara, G. Tarzia, M. Mor and D. Piomelli, Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties, J Pharmacol Exp Ther 318 (2006), 563-1270
4. M.A. Atkin, A. Gasper, R. Ullegaddi and H.J. Powers, Oxidative susceptibility of unfractionated serum or plasma: response to antioxidants in vitro and to antioxidant supplementation, Clin Chem 51 (2005), 2138-2144.
5. M. Aviram, M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, C.L. Bisgaier, R.S. Newton and B. La Du, Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants, Free Radic Biol Med 26 (1999), 892-904.
6. P.J. Barter, S. Nicholls, K.A. Rye, G.M. Anantharamaiah, M. Navab and A.M. Fogelman, Antiinflammatory properties of HDL, Circ Res 95 (2004), 764-772.
7. E.V. Berdyshev, E. Boichot, N. Germain, N. Allain, J.P. Anger and V. Lagente, Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells, Eur J Pharmacol 330 (1997), 231-240.
8. I.N. Bojesena and H.S. Hansen, Binding of anandamide to bovine serum albumin, J Lipid Res 44 (2003), 1790-1794. (Pubitemid 37185891)
9. V.W. Bowry, K.K. Stanley and R. Stocker, High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors, Proc Natl Acad Sci USA 89 (1992), 10316-10320.
10. M. Côté, I. Matias, I. Lemieux, S. Petrosino, N. Alméras, J.P. Després and V. Di Marzo, Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men, Int J Obes (Lond) 31 (2007), 692-699.
11. N.A. Darmani, A.A. Izzo, B. Degenhardt, M.Valenti, G. Scaglione, R. Papasso, I. Sorrentini and V. Di Marzo, Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies, Neuropharmacology 48 (2005), 1154-1163.
12. M. Degn, K.L. Lambertsen, G. Petersen, M. Meldgaard, A. Artmann, B.H. Clausen, S.H. Hansen, B. Finsen, H.S. Hansen and T.M. Lund, Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice, J Neurochem 103 (2007), 1907-1916. (Pubitemid 350126623)
13. P.N. Durrington, B. Mackness and M.I. Mackness, Paraoxonase and atherosclerosis, Arterioscler Thromb Vasc Biol 2 (2001), 473-480.
14. G. Ferretti, T. Bacchetti, C. Moroni, S. Savino, A. Liuzzi, F. Balzala andV. Bicchiega, Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females, J Clin Endocrinol Metab 90 (2005), 1728-1733.
15. G. Ferretti, T. Bacchetti, F. Principi, F. Di Ludovico, B. Viti, V.A. Angeleri, M. Danni and L. Provinciali, Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity, Mult Scler 11 (2005), 677-682.
16. H.S. Hansen and A. Artmann, Endocannabinoids and nutrition, J Neuroendocrinol 20 (2008), 94-99.
17. H.S. Hansen, B. Moesgaard, H.H. Hansen and G. Petersen, N-Acylethanolamines and precursor phospholipids- relation to cell injury, Chem Phys Lipids 108 (2000), 135-150.
18. H.H. Hansen, C. Ikonomidou, P. Bittigau and H.S. Hansen, Accumulation of the anandamide precursor and other Nacylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death, J Neurochem 76 (2001), 39-46.
19. M. Harangi, I. Seres, M.T. Magyar, I. Csipo, S. Sipka, A. Valikovics, L. Csiba, D. Bereczki and G. Paragh, Association between human paraoxonase 1 activity and intima-media thickness in subjects under 55 years of age with carotid artery disease, Cerebrovasc Dis 25 (2008), 122-128.
20. H. Jakubowski, Calcium-dependent human serum homocysteine thiolactone hydrolase, A protective mechanism against protein N-homocysteinylation, J Biol Chem 275 (2000), 3957-3962.
21. B. Karten, U. Beisiegel, G. Gercken and A. Kontush, Mechanisms of lipid peroxidation in human blood plasma: a kinetic approach, Chem Phys Lipids 88 (1997), 83-96. (Pubitemid 27417669)
22. I. Kaufmann, G. Schelling, C. Eisner, H.P. Richter, T. Krauseneck, M. Vogeser, D. Hauer, P. Campolongo, A. Chouker, A. Beyer and M. Thiel, Anandamide and neutrophil function in patients with fibromyalgia, Psychoneuroendocrinology 33 (2008), 676-685.
23. B.N. La Du, S. Adkins, C.L. Kuo and D. Lipsig, Studies on human serum paraoxonase/arylesterase, Chem Biol Interact 87 (1993), 25-34.
24. D.M. Lambert and C.J. Fowler, The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications, J Med Chem 48 (2005), 5059-5087.
25. D.M. Lambert, S. Vandevoorde, K.O. Jonsson and C.J. Fowler, The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 9 (2002), 663-674. (Pubitemid 34296196)
26. C. Lee, J. Barnett and P.D. Reaven, Liposomes enriched in oleic acid are less susceptible to oxidation and have less proinflammatory activity when exposed to oxidizing conditions, J Lipid Res 39 (1998), 1239-1247.
27. J. Lo Verme, S. Gaetani, J. Fu, F. Oveisi, K. Burton and D. Piomelli, Regulation of food intake by oleoylethanolamide, Cell Mol Life Sci 62 (2005), 708-716.
28. G. Lombardi, G. Miglio, F. Varsaldi, A. Minassi and G. Appendino, Oxyhomologation of the amide bond potentiates neuroprotective effects of the endolipid N-palmitoylethanolamine, J Pharmacol Exp Ther 320 (2007), 599-606.
29. M. Maccarrone, M. Bari, N. Battista and A. Finazzi-Agro, Endocannabinoid degradation, endotoxic shock and inflammation, Curr Drug Targets Inflamm Allergy 1 (2002), 53-63.
30. M.I. Mackness, P.N. Durrington and B. Mackness, The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention, Am J Cardiovasc Drugs 4 (2004), 211-217. (Pubitemid 39206616)
31. S.D. Nguyen and D.E. Sok, Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action, Free Radic Res 37 (2003), 1319-1330. (Pubitemid 37441715)
32. J. Nourooz-Zadeh, Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma, Methods Enzymol 300 (1999), 58-62.
33. J. Nourooz-Zadeh, J. Tajaddini-Sarmadi, K.L. Ling and S.P. Wolff, Low-density lipoprotein is the major carrier of lipid hydroperoxides in plasma, Relevance to determination of total plasma lipid hydroperoxide concentrations, Biochem J 313 (1996), 781-786. (Pubitemid 26050808)
34. M.D. Randall, Endocannabinoids and the haematological system, Br J Pharmacol 152 (2007), 671-675.
35. E. Schnitzer, I. Pinchuk, A. Bor, M. Fainaru, A.M. Samuni and D. Lichtenberg, Lipid oxidation in unfractionated serum and plasma, Chem Phys Lipids 92 (1998), 151-170.
36. D. Schreiber, S. HarlWnger, B.M. Nolden, C.W. Gerth, U. Jaehde, E. Schömig, J. Klosterkötter, A. Giuffrida, G. Astarita, D. Piomelli and F.M. Leweke, Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry, Analytical Biochemistry 361 (2007), 162-168.
37. W.G. Smith, J. Wang, A. Dang, C. Reeves, D. Bibbs and F.H. Faas, Lipoprotein susceptibility to oxidation in the macromolecular fraction of plasma: relation to plasma lipids and oleate/linoleate ratio in comparison with whole plasma in hypertriglyceridemia, Clin Chim Acta 316 (2002), 11-17.
38. A.D. Watson, J.A. Berliner, S.Y. Hama, B.N. La Du, K.F. Faull, A.M. Fogelman and M. Navab, Protective effect of high density lipoprotein associated paraoxonase, Inhibition of the biological activity of minimally oxidized low density lipoprotein, J Clin Invest 96 (1995), 2882-2891.
39. G. Zolese, G. Falcioni, E. Bertoli, R. Galeazzi, M. Wozniak, Z. Wypych, E. Gratton and A. Ambrosini, Steady-state and time resolved fluorescence of albumins interacting with N-oleylethanolamine, a component of the endogenous N-acylethanolamines, Proteins 40 (2000), 39-48.
40. G. Zolese, T. Bacchetti, A. Ambrosini, M. Wozniak, E. Bertoli and G. Ferretti, Increased plasma concentrations of palmitoylethanolamide, an endogenous fatty acid amide, affect oxidative damage of human low-density lipoproteins: an in vitro study, Atherosclerosis 182 (2005), 47-55.